Standout Papers

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma:... 2022 2026 2023 2024222
  1. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study (2022)
    Lihua E. Budde, Laurie H. Sehn et al. The Lancet Oncology

Immediate Impact

3 by Nobel laureates 6 from Science/Nature 60 standout
Sub-graph 1 of 21

Citing Papers

The present and future of bispecific antibodies for cancer therapy
2024 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
8 intermediate papers

Works of Chi‐Chung Li being referenced

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
2022 Standout
Modeling Ophthalmic Drug Delivery by Soaked Contact Lenses
2006
and 5 more

Author Peers

Author Last Decade Papers Cites
Chi‐Chung Li 586 293 345 385 363 54 1.7k
Diana S‐L Chow 345 126 91 145 321 76 2.0k
Alexander Schwarz 173 458 235 60 362 112 1.8k
Takashi Watanabe 601 311 209 78 444 123 1.9k
Liya Wang 155 129 462 232 46 82 1.8k
Qin Chen 211 218 85 98 62 64 1.7k
GJ Ossenkoppele 589 111 74 169 122 32 2.0k
Anà Hennino 324 919 72 145 101 54 2.2k
K. Hellmann 718 98 195 63 130 100 2.2k
Marı́a J. Garrido 291 145 102 79 41 64 1.5k
Arnold Lee 420 180 114 64 97 69 1.5k

All Works

Loading papers...

Rankless by CCL
2026